Gastric Cancer
Conditions
Interventions
Research group:Aipalolitovorili 5mg/kg, Tegio 40mg/m^2, Oxaliplatin 130mg/m^2
Sponsors
The First Affiliated Hospital of Bengbu Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Clinically confirmed metastatic gastric cancer or gastroesophageal junction adenocarcinoma; 2. ECOG PS score =1; 3. At least one measurable lesion (RECIST 1.1 criteria); 4. Adequate bone marrow reserve and good organ function; 5. Age 18-70 years; 6. Male or non-pregnant, non-lactating female; 7. Expected survival over 6 months; 8. Disease stabilization or progression after first-line guideline-recommended therapy.
Exclusion criteria
Exclusion criteria: 1. Received other radiotherapy, chemotherapy, targeted therapy, or immunotherapy within the past 4 weeks; 2. Presence of autoimmune diseases; 3. Require the use of immunosuppressants; 4. Concurrent other malignant tumors; 5. Severe impairment of liver and kidney function, cardiopulmonary function, or coagulation disorders, or presence of severe underlying diseases that cannot tolerate chemotherapy; 6. Severe mental illness or uncontrolled infectious diseases; 7. ECOG performance status score > 2; 8. Other clinical or laboratory conditions deemed by the investigator as unsuitable for the patient to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate (ORR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease Control Rate (DCR);Progression-Free Survival (PFS);Overall Survival (OS);Safety; | — |
Countries
China
Contacts
Public ContactYangang Zhang
The First Affiliated Hospital of Bengbu Medical University
Outcome results
None listed